Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $5.08 USD
Change Today +0.10 / 2.01%
Volume 36.0K
ALQA On Other Exchanges
As of 8:10 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

alliqua biomedical inc (ALQA) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/9/15 - $6.55
52 Week Low
10/28/14 - $3.70
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

alliqua biomedical inc (ALQA) Related Businessweek News

No Related Businessweek News Found

alliqua biomedical inc (ALQA) Details

Alliqua BioMedical, Inc. provides wound care solutions. The company offers Extracellular Matrix, a suite of advanced wound management products; Biovance, a decellularized and dehydrated allograft for the management of non-infected partial-and full-thickness wounds; SilverSeal, a hydrogel wound dressing with silver coated fibers; and Hydress, an over-the-counter hydrogel wound dressing. It also provides contact dressings, island dressings, and wraps using TheraBond 3D antimicrobial barrier systems. In addition, the company offers Sorbion sachet S, a primary dressing for exudating wounds, such as surgical wounds, venous leg ulcers, and diabetic ulcers; Sorbion sana, a primary wound dressing that provides an another form of wound treatment; and products with hydrokinetic fibers as primary dressings. Further, it provides contract manufacturing services, including the development, manufacture, and market of high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company has a license, marketing, and development agreement with Anthrogenesis Corporation for the development and commercialization of Extracellular Matrix and Biovance products. Alliqua BioMedical, Inc. primarily serves medical device manufacturers through its direct sales force; and an independent network of agents. The company is headquartered in Langhorne, Pennsylvania.

50 Employees
Last Reported Date: 05/14/15

alliqua biomedical inc (ALQA) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $682.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $376.8K
Chief Operating Officer
Total Annual Compensation: $376.8K
Compensation as of Fiscal Year 2014.

alliqua biomedical inc (ALQA) Key Developments

Alliqua BioMedical, Inc. Announces the Publication of Results from Biovance Use Registry Study in WOUNDS

Alliqua BioMedical, Inc. announced that a review of an observational study, focusing on the use of the company's Biovance Amniotic Tissue Allograft to treat chronic wounds was published in WOUNDS, the most widely-read, peer-reviewed journal focusing on wound care and wound research. It is focused on the chronic wound data subset from a larger observational study with 230 subjects/244 chronic and acute wounds at 19 centers across the US. This review includes 165 subjects with 179 chronic wounds across the 15 wound care centers that treated chronic wounds.

Alliqua BioMedical, Inc. Announces Executive Changes

Alliqua BioMedical, Inc. announced the appointment of Nino Pionati to the position of Chief Strategy and Marketing Officer. The company also announced that, following a distinguished career in the wound care sector, Chief Marketing Officer, Lori Toner, intends to retire at the end of the month. Nino Pionati joins Alliqua BioMedical from Bayer HealthCare Pharmaceuticals, where he was the Vice President of Marketing for Bayer's Essure portfolio and a member of the Global Franchise and Women's Health Care Leadership teams. Prior to joining Bayer, Mr. Pionati spent over 14 years at ConvaTec and Bristol Myers Squibb, where he held several global marketing positions at the corporate level, including President of Global Marketing, Business Development and International and President of the Intercontinental Region.

Alliqua Biomedical, Inc. Obtains Senior Secured Term Loan

Alliqua BioMedical, Inc. announced that it has obtained a Senior Secured Term Loan from Perceptive Advisors in the principal amount of $15.5 million to finance the initial cash purchase price of the acquisition.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALQA:US $5.08 USD +0.10

ALQA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Derma Sciences Inc $7.20 USD +0.05
MiMedx Group Inc $10.21 USD -0.52
Osiris Therapeutics Inc $21.29 USD -0.04
Smith & Nephew PLC 1,189 GBp +1.00
View Industry Companies

Industry Analysis


Industry Average

Valuation ALQA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.7x
Price/Book 4.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALLIQUA BIOMEDICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at